Midatech Pharma PLC (MTP): Price and Financial Metrics


Midatech Pharma PLC (MTP): $0.58

0.02 (+4.04%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MTP to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MTP Stock Price Chart Interactive Chart >

Price chart for MTP

MTP Price/Volume Stats

Current price $0.58 52-week high $3.61
Prev. close $0.56 52-week low $0.38
Day low $0.51 Volume 21,500
Day high $0.60 Avg. volume 59,462
50-day MA $0.75 Dividend yield N/A
200-day MA $1.25 Market Cap 7.39M

Midatech Pharma PLC (MTP) Company Bio


Midatech Pharma PLC focuses on the development and commercialization of multiple, high-value, targeted therapies for major diseases with high unmet medical need in the nanomedicine field.


MTP Latest News Stream


Event/Time News Detail
Loading, please wait...

MTP Latest Social Stream


Loading social stream, please wait...

View Full MTP Social Stream

Latest MTP News From Around the Web

Below are the latest news stories about Midatech Pharma Plc that investors may wish to consider to help them evaluate MTP as an investment opportunity.

Midatech Pharma PLC Announces Extension of Janssen collaboration re Q-Sphera

Midatech announces extension of R&D collaboration with Janssen focused on Q-Sphera technologyABINGDON, UK / ACCESSWIRE / January 17, 2022 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce the extension of its R&D collaboration with Janssen Pharmaceutica NV (Janssen) originally announced on 21 July 2020.On 17 June 2021, the Company announced that, using its Q-Sphera techno

Yahoo | January 17, 2022

Midatech Pharma plc (NASDAQ: MTP) Stock Forecast: Downside Of -111583.69% By 2021

The trading price of Midatech Pharma plc (NASDAQ:MTP) closed higher on Monday, December 13, closing at $1.41, 6.02% higher than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Stocks Register | December 14, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back, investor!

William White on InvestorPlace | December 13, 2021

Midatech Pharmas IND application for a Phase 1 study of MTX110 has been cleared by the US FDA

Midatech Pharma PLC (LON:MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced that its Investigational New Drug (IND) application for a Phase 1 study of MTX110, a panobinostat complex to be administered by convection enhanced delivery in patients with recurrent glioblastoma multiforme (rGBM), has been cleared by []

Directors Talk | December 13, 2021

Midatech Pharma''s IND application for a Phase 1 study of MTX110 has been cleared by the US FDA - DirectorsTalk Interviews

Midatech Pharma''s IND application for a Phase 1 study of MTX110 has been cleared by the US FDA

DirectorsTalk | December 13, 2021

Read More 'MTP' Stories Here

MTP Price Returns

1-mo -22.67%
3-mo -41.88%
6-mo -60.70%
1-year -72.12%
3-year -92.66%
5-year -99.60%
YTD -44.76%
2021 -43.85%
2020 -45.74%
2019 -55.53%
2018 -81.55%
2017 -69.57%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.842 seconds.